The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop packaging cell lines containing the novel vector and to use these commercially for the contract manufacturing of gene therapeutics.
Scientists at the MHH previously showed that the vector system can be flexibly adapted to various applications and is produced efficiently in cell lines normally used in the production of biopharmaceuticals. Ascenion, the MHH’s exclusive technology transfer partner, facilitated the commercialization of the invention, from the patent application to forging the cooperation and negotiating the licensing agreement.
The MHH vector represents an advancement over conventional vector systems, whose therapeutic efficacy has already been established in many indications. “We have created a new platform with broad applications in gene therapy that offers improved safety to patients and increased cost-effectiveness to developers and healthcare systems,” says Prof. Christopher Baum, Director of the Institute for Experimental Haematology at the MHH. Prof. Baum developed the vector system together with his colleagues Dr Julia Sürth and Dr Dr Axel Schambach, supported in part by funding from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence REBIRTH (from Regenerative Biology to Reconstructive Therapy).
The main areas of application range from introducing therapeutic genes into blood stem cells and lymphocytes in order to correct congenital defects, to improving cellular immunity in cancer and HIV infection. Further cell types and diseases are also being targeted using the new vector system.
Prof. Roland Wagner, Senior Vice President Development at Rentschler Biotechnologie GmbH, emphasizes: “The new vector system complements our spectrum for the development of virus-based biologics used in gene therapy and virotherapy, which, beside Rentschler’s own AAV vector technology, will be made available to our clients for the development of these products.” Rentschler is currently financing further research at the MHH on highly efficient and stable packaging cell lines for retroviral vectors.
Ascenion will continue to assist with the project. “We are delighted that the research findings from the MHH have been developed to the benefit of patients,” commented Dr Christian Stein, Ascenion’s CEO. “The partners complement each other perfectly: the MHH contributes its innovative technology and proximity to patients, and Rentschler contributes its longstanding experience in the production of biopharmaceuticals and its tight industry network.”
Further information at www.ascenion.de
About the Hannover Medical School (MHH)
Hannover Medical School (MHH), founded in 1965, is one of Germany's leading universities in research, patient care and teaching. With its concentrated support of specialised research areas, it has become one of the best university clinics in the country. The outstanding research conducted at Germany's only institution of higher education exclusively devoted to medicine has been clearly recognised within the framework of the Excellence Initiative supported by the federal and state governments.
Further information at www.mh-hannover.de
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years’ experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1000 and 2500 liters, allowing the production of material for clinical trials (Phases I to III) and for market supply, and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Further information at www.rentschler.de
GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University
Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center
At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.
Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
25.04.2018 | Physics and Astronomy
25.04.2018 | Physics and Astronomy
25.04.2018 | Information Technology